nodes	percent_of_prediction	percent_of_DWPC	metapath
Flurandrenolide—Corticosteroid Hormone Receptor Agonists—Prednisone—prostate cancer	0.513	1	CiPCiCtD
Flurandrenolide—NR3C1—prostate cancer	0.19	1	CbGaD
Flurandrenolide—NR3C1—Prednisone—prostate cancer	0.0255	1	CbGbCtD
Flurandrenolide—Ciclesonide—Prednisone—prostate cancer	0.0192	0.0834	CrCrCtD
Flurandrenolide—Hydrocortamate—Prednisone—prostate cancer	0.0161	0.0697	CrCrCtD
Flurandrenolide—Fluocortolone—Prednisone—prostate cancer	0.0147	0.0637	CrCrCtD
Flurandrenolide—Alclometasone—Prednisone—prostate cancer	0.0143	0.0619	CrCrCtD
Flurandrenolide—Amcinonide—Prednisone—prostate cancer	0.0139	0.0603	CrCrCtD
Flurandrenolide—Budesonide—Prednisone—prostate cancer	0.0139	0.0603	CrCrCtD
Flurandrenolide—Fludrocortisone—Prednisone—prostate cancer	0.0135	0.0587	CrCrCtD
Flurandrenolide—Desonide—Prednisone—prostate cancer	0.0135	0.0587	CrCrCtD
Flurandrenolide—Diflorasone—Prednisone—prostate cancer	0.0135	0.0587	CrCrCtD
Flurandrenolide—Flunisolide—Prednisone—prostate cancer	0.0135	0.0587	CrCrCtD
Flurandrenolide—Paramethasone—Prednisone—prostate cancer	0.0132	0.0572	CrCrCtD
Flurandrenolide—Dexamethasone—Prednisone—prostate cancer	0.0123	0.0533	CrCrCtD
Flurandrenolide—Rimexolone—Prednisone—prostate cancer	0.0123	0.0533	CrCrCtD
Flurandrenolide—Betamethasone—Prednisone—prostate cancer	0.0123	0.0533	CrCrCtD
Flurandrenolide—Methylprednisolone—Prednisone—prostate cancer	0.0118	0.051	CrCrCtD
Flurandrenolide—Prednisolone—Prednisone—prostate cancer	0.0115	0.0499	CrCrCtD
Flurandrenolide—Hydrocortisone—Prednisone—prostate cancer	0.011	0.0479	CrCrCtD
Flurandrenolide—Allergic contact dermatitis—Estradiol—prostate cancer	0.00113	0.051	CcSEcCtD
Flurandrenolide—NR3C1—urine—prostate cancer	0.000856	0.26	CbGeAlD
Flurandrenolide—Skin atrophy—Prednisone—prostate cancer	0.000725	0.0328	CcSEcCtD
Flurandrenolide—Skin striae—Prednisone—prostate cancer	0.000688	0.0311	CcSEcCtD
Flurandrenolide—Eruption—Estradiol—prostate cancer	0.000641	0.029	CcSEcCtD
Flurandrenolide—Secondary infection—Epirubicin—prostate cancer	0.000582	0.0263	CcSEcCtD
Flurandrenolide—Hypertrichosis—Prednisone—prostate cancer	0.000576	0.026	CcSEcCtD
Flurandrenolide—Skin discolouration—Goserelin—prostate cancer	0.00055	0.0249	CcSEcCtD
Flurandrenolide—Secondary infection—Doxorubicin—prostate cancer	0.000539	0.0244	CcSEcCtD
Flurandrenolide—Leukoderma—Prednisone—prostate cancer	0.000515	0.0233	CcSEcCtD
Flurandrenolide—SERPINA6—renal system—prostate cancer	0.000478	0.145	CbGeAlD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—TMPRSS2—prostate cancer	0.000461	0.0364	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Estradiol—prostate cancer	0.000436	0.0197	CcSEcCtD
Flurandrenolide—Eruption—Docetaxel—prostate cancer	0.000413	0.0187	CcSEcCtD
Flurandrenolide—Leukoderma—Epirubicin—prostate cancer	0.000403	0.0182	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—HOXB13—prostate cancer	0.000392	0.031	CbGpPWpGaD
Flurandrenolide—Dermatitis contact—Estradiol—prostate cancer	0.000389	0.0176	CcSEcCtD
Flurandrenolide—Infection—Abiraterone—prostate cancer	0.000384	0.0174	CcSEcCtD
Flurandrenolide—Leukoderma—Doxorubicin—prostate cancer	0.000373	0.0168	CcSEcCtD
Flurandrenolide—SERPINA6—bone marrow—prostate cancer	0.000362	0.11	CbGeAlD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—FOXA3—prostate cancer	0.000345	0.0273	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Etoposide—prostate cancer	0.000338	0.0153	CcSEcCtD
Flurandrenolide—NR3C1—prostate gland—prostate cancer	0.000307	0.0932	CbGeAlD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—KLK3—prostate cancer	0.000297	0.0235	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—SPOCK1—prostate cancer	0.000297	0.0235	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—KLF15—prostate cancer	0.000297	0.0235	CbGpPWpGaD
Flurandrenolide—Infection—Cabazitaxel—prostate cancer	0.000295	0.0133	CcSEcCtD
Flurandrenolide—Pruritus—Estramustine—prostate cancer	0.000282	0.0127	CcSEcCtD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—FOXA1—prostate cancer	0.000281	0.0222	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—KLK2—prostate cancer	0.000279	0.0221	CbGpPWpGaD
Flurandrenolide—Eruption—Epirubicin—prostate cancer	0.000278	0.0126	CcSEcCtD
Flurandrenolide—Folliculitis—Epirubicin—prostate cancer	0.000272	0.0123	CcSEcCtD
Flurandrenolide—Skin discolouration—Capecitabine—prostate cancer	0.000272	0.0123	CcSEcCtD
Flurandrenolide—Amcinonide—ANXA1—prostate cancer	0.000269	0.0848	CrCbGaD
Flurandrenolide—Pruritus—Estrone—prostate cancer	0.000269	0.0122	CcSEcCtD
Flurandrenolide—NR3C1—seminal vesicle—prostate cancer	0.00026	0.0789	CbGeAlD
Flurandrenolide—Eruption—Doxorubicin—prostate cancer	0.000258	0.0116	CcSEcCtD
Flurandrenolide—Infection—Bicalutamide—prostate cancer	0.000253	0.0115	CcSEcCtD
Flurandrenolide—Folliculitis—Doxorubicin—prostate cancer	0.000252	0.0114	CcSEcCtD
Flurandrenolide—Rash—Estramustine—prostate cancer	0.000251	0.0113	CcSEcCtD
Flurandrenolide—Dermatitis—Estramustine—prostate cancer	0.000251	0.0113	CcSEcCtD
Flurandrenolide—Pruritus—Nilutamide—prostate cancer	0.00025	0.0113	CcSEcCtD
Flurandrenolide—Pruritus—Flutamide—prostate cancer	0.000249	0.0112	CcSEcCtD
Flurandrenolide—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000244	0.0111	CcSEcCtD
Flurandrenolide—Rash—Abiraterone—prostate cancer	0.000244	0.011	CcSEcCtD
Flurandrenolide—Dermatitis—Abiraterone—prostate cancer	0.000243	0.011	CcSEcCtD
Flurandrenolide—Rash—Estrone—prostate cancer	0.00024	0.0108	CcSEcCtD
Flurandrenolide—Dermatitis—Estrone—prostate cancer	0.00024	0.0108	CcSEcCtD
Flurandrenolide—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000235	0.0106	CcSEcCtD
Flurandrenolide—Hypersensitivity—Degarelix—prostate cancer	0.000232	0.0105	CcSEcCtD
Flurandrenolide—NR3C1—epithelium—prostate cancer	0.000226	0.0685	CbGeAlD
Flurandrenolide—Pruritus—Degarelix—prostate cancer	0.000223	0.0101	CcSEcCtD
Flurandrenolide—Rash—Nilutamide—prostate cancer	0.000223	0.0101	CcSEcCtD
Flurandrenolide—Dermatitis—Nilutamide—prostate cancer	0.000222	0.0101	CcSEcCtD
Flurandrenolide—Rash—Flutamide—prostate cancer	0.000222	0.01	CcSEcCtD
Flurandrenolide—Dermatitis—Flutamide—prostate cancer	0.000221	0.01	CcSEcCtD
Flurandrenolide—Medroxyprogesterone Acetate—HSD3B2—prostate cancer	0.000221	0.0698	CrCbGaD
Flurandrenolide—Hypersensitivity—Cabazitaxel—prostate cancer	0.000219	0.0099	CcSEcCtD
Flurandrenolide—Infection—Ethinyl Estradiol—prostate cancer	0.000214	0.00968	CcSEcCtD
Flurandrenolide—NR3C1—renal system—prostate cancer	0.000209	0.0636	CbGeAlD
Flurandrenolide—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000209	0.00946	CcSEcCtD
Flurandrenolide—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000209	0.00945	CcSEcCtD
Flurandrenolide—NR3C1—urethra—prostate cancer	0.000206	0.0624	CbGeAlD
Flurandrenolide—Rash—Degarelix—prostate cancer	0.000199	0.00899	CcSEcCtD
Flurandrenolide—Dermatitis—Degarelix—prostate cancer	0.000199	0.00899	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—FOXA1—prostate cancer	0.000199	0.0157	CbGpPWpGaD
Flurandrenolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—EGR1—prostate cancer	0.000197	0.0156	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Epirubicin—prostate cancer	0.00019	0.00857	CcSEcCtD
Flurandrenolide—Hypersensitivity—Bicalutamide—prostate cancer	0.000188	0.00849	CcSEcCtD
Flurandrenolide—Pruritus—Bicalutamide—prostate cancer	0.00018	0.00815	CcSEcCtD
Flurandrenolide—Infection—Goserelin—prostate cancer	0.000176	0.00797	CcSEcCtD
Flurandrenolide—Skin discolouration—Doxorubicin—prostate cancer	0.000175	0.00793	CcSEcCtD
Flurandrenolide—Infection—Conjugated Estrogens—prostate cancer	0.000175	0.00789	CcSEcCtD
Flurandrenolide—Dermatitis contact—Epirubicin—prostate cancer	0.000169	0.00765	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—NKX3-1—prostate cancer	0.000165	0.0131	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—RXRA—prostate cancer	0.000164	0.013	CbGpPWpGaD
Flurandrenolide—Rash—Bicalutamide—prostate cancer	0.000161	0.00727	CcSEcCtD
Flurandrenolide—Dermatitis—Bicalutamide—prostate cancer	0.000161	0.00726	CcSEcCtD
Flurandrenolide—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000159	0.00718	CcSEcCtD
Flurandrenolide—NR3C1—bone marrow—prostate cancer	0.000158	0.0481	CbGeAlD
Flurandrenolide—NR3C1—Endoderm Differentiation—LAMC1—prostate cancer	0.000157	0.0124	CbGpPWpGaD
Flurandrenolide—Dermatitis contact—Doxorubicin—prostate cancer	0.000157	0.00708	CcSEcCtD
Flurandrenolide—Pruritus—Ethinyl Estradiol—prostate cancer	0.000152	0.00689	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—LIFR—prostate cancer	0.000145	0.0115	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—KLF6—prostate cancer	0.000145	0.0115	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—MT2A—prostate cancer	0.000144	0.0114	CbGpPWpGaD
Flurandrenolide—Infection—Estradiol—prostate cancer	0.00014	0.00632	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—PENK—prostate cancer	0.000137	0.0108	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—LAMC1—prostate cancer	0.000136	0.0108	CbGpPWpGaD
Flurandrenolide—Rash—Ethinyl Estradiol—prostate cancer	0.000136	0.00614	CcSEcCtD
Flurandrenolide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000136	0.00614	CcSEcCtD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOA2—prostate cancer	0.000135	0.0107	CbGpPWpGaD
Flurandrenolide—NR3C1—testis—prostate cancer	0.000135	0.0411	CbGeAlD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—prostate cancer	0.000131	0.0103	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Goserelin—prostate cancer	0.000131	0.00591	CcSEcCtD
Flurandrenolide—Infection—Mitoxantrone—prostate cancer	0.00013	0.00588	CcSEcCtD
Flurandrenolide—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000129	0.00585	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—HNF1B—prostate cancer	0.000128	0.0101	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—BMP7—prostate cancer	0.000128	0.0101	CbGpPWpGaD
Flurandrenolide—Pruritus—Goserelin—prostate cancer	0.000125	0.00567	CcSEcCtD
Flurandrenolide—Pruritus—Conjugated Estrogens—prostate cancer	0.000124	0.00562	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—ID3—prostate cancer	0.000123	0.00974	CbGpPWpGaD
Flurandrenolide—Medroxyprogesterone Acetate—AKR1C3—prostate cancer	0.000123	0.0387	CrCbGaD
Flurandrenolide—NR3C1—Nuclear Receptors—ESR2—prostate cancer	0.000121	0.00957	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—LEP—prostate cancer	0.000119	0.00942	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOA1—prostate cancer	0.000114	0.00901	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—ANXA1—prostate cancer	0.000113	0.0357	CrCbGaD
Flurandrenolide—Rash—Goserelin—prostate cancer	0.000112	0.00506	CcSEcCtD
Flurandrenolide—Dermatitis—Goserelin—prostate cancer	0.000112	0.00505	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—ASCL1—prostate cancer	0.000112	0.00882	CbGpPWpGaD
Flurandrenolide—Rash—Conjugated Estrogens—prostate cancer	0.000111	0.00501	CcSEcCtD
Flurandrenolide—Dermatitis—Conjugated Estrogens—prostate cancer	0.000111	0.005	CcSEcCtD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—RXRA—prostate cancer	0.000108	0.00857	CbGpPWpGaD
Flurandrenolide—Infection—Etoposide—prostate cancer	0.000108	0.00489	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptors—AR—prostate cancer	0.000107	0.00846	CbGpPWpGaD
Flurandrenolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAP2K1—prostate cancer	0.000107	0.00846	CbGpPWpGaD
Flurandrenolide—Dexamethasone—CYP3A43—prostate cancer	0.000107	0.0337	CrCbGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—IRS1—prostate cancer	0.000106	0.0084	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptors—RXRA—prostate cancer	0.000106	0.00839	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Estradiol—prostate cancer	0.000104	0.00468	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—NPPA—prostate cancer	0.000104	0.00818	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—NCOA2—prostate cancer	0.000102	0.00802	CbGpPWpGaD
Flurandrenolide—Pruritus—Estradiol—prostate cancer	9.95e-05	0.0045	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—NCOA2—prostate cancer	9.86e-05	0.00779	CbGpPWpGaD
Flurandrenolide—NR3C1—lymph node—prostate cancer	9.81e-05	0.0298	CbGeAlD
Flurandrenolide—NR3C1—AP-1 transcription factor network—ATF3—prostate cancer	9.81e-05	0.00775	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Mitoxantrone—prostate cancer	9.65e-05	0.00436	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptors—VDR—prostate cancer	9.62e-05	0.0076	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—ESR2—prostate cancer	9.58e-05	0.00757	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—PTHLH—prostate cancer	9.01e-05	0.00712	CbGpPWpGaD
Flurandrenolide—Infection—Docetaxel—prostate cancer	9e-05	0.00407	CcSEcCtD
Flurandrenolide—Rash—Estradiol—prostate cancer	8.86e-05	0.00401	CcSEcCtD
Flurandrenolide—Dermatitis—Estradiol—prostate cancer	8.86e-05	0.004	CcSEcCtD
Flurandrenolide—Clocortolone—NR3C1—prostate cancer	8.77e-05	0.0276	CrCbGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ATF3—prostate cancer	8.73e-05	0.00689	CbGpPWpGaD
Flurandrenolide—Infection—Capecitabine—prostate cancer	8.71e-05	0.00394	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—EGR1—prostate cancer	8.69e-05	0.00686	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—MIF—prostate cancer	8.62e-05	0.00681	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—NCOA1—prostate cancer	8.56e-05	0.00676	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—AR—prostate cancer	8.46e-05	0.00668	CbGpPWpGaD
Flurandrenolide—Dexamethasone—ANXA1—prostate cancer	8.46e-05	0.0266	CrCbGaD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—RXRA—prostate cancer	8.39e-05	0.00663	CbGpPWpGaD
Flurandrenolide—Drospirenone—AR—prostate cancer	8.38e-05	0.0264	CrCbGaD
Flurandrenolide—NR3C1—Circadian Clock—NCOA1—prostate cancer	8.31e-05	0.00656	CbGpPWpGaD
Flurandrenolide—Desonide—NR3C1—prostate cancer	8.3e-05	0.0261	CrCbGaD
Flurandrenolide—Diflorasone—NR3C1—prostate cancer	8.3e-05	0.0261	CrCbGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—PPARA—prostate cancer	8.29e-05	0.00655	CbGpPWpGaD
Flurandrenolide—Rash—Mitoxantrone—prostate cancer	8.26e-05	0.00373	CcSEcCtD
Flurandrenolide—Dermatitis—Mitoxantrone—prostate cancer	8.25e-05	0.00373	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—EZH2—prostate cancer	8.21e-05	0.00648	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—AR—prostate cancer	8.2e-05	0.00648	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—BGLAP—prostate cancer	8.19e-05	0.00647	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—RXRA—prostate cancer	8.14e-05	0.00643	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptors—PPARA—prostate cancer	8.11e-05	0.00641	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Etoposide—prostate cancer	8.03e-05	0.00363	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—RXRA—prostate cancer	7.9e-05	0.00624	CbGpPWpGaD
Flurandrenolide—Fludrocortisone—AR—prostate cancer	7.89e-05	0.0248	CrCbGaD
Flurandrenolide—Infection—Prednisone—prostate cancer	7.76e-05	0.00351	CcSEcCtD
Flurandrenolide—Pruritus—Etoposide—prostate cancer	7.71e-05	0.00349	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—VDR—prostate cancer	7.6e-05	0.006	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—PRKACB—prostate cancer	7.59e-05	0.006	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—SIRT1—prostate cancer	7.48e-05	0.00591	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—TH—prostate cancer	7.38e-05	0.00583	CbGpPWpGaD
Flurandrenolide—Medrysone—NR3C1—prostate cancer	7.35e-05	0.0232	CrCbGaD
Flurandrenolide—NR3C1—Nuclear Receptors—ESR1—prostate cancer	7.35e-05	0.00581	CbGpPWpGaD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—prostate cancer	7.35e-05	0.00581	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOA2—prostate cancer	7.23e-05	0.00571	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—HSP90B1—prostate cancer	7.2e-05	0.00569	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—NCOA2—prostate cancer	7.16e-05	0.00566	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—EGR1—prostate cancer	6.95e-05	0.00549	CbGpPWpGaD
Flurandrenolide—Rash—Etoposide—prostate cancer	6.87e-05	0.00311	CcSEcCtD
Flurandrenolide—Dermatitis—Etoposide—prostate cancer	6.86e-05	0.0031	CcSEcCtD
Flurandrenolide—Hydrocortamate—NR3C1—prostate cancer	6.86e-05	0.0216	CrCbGaD
Flurandrenolide—Hypersensitivity—Docetaxel—prostate cancer	6.67e-05	0.00302	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—GJA1—prostate cancer	6.62e-05	0.00523	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—prostate cancer	6.58e-05	0.0052	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—AHR—prostate cancer	6.48e-05	0.00512	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Capecitabine—prostate cancer	6.46e-05	0.00292	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—PPARA—prostate cancer	6.41e-05	0.00506	CbGpPWpGaD
Flurandrenolide—Pruritus—Docetaxel—prostate cancer	6.41e-05	0.0029	CcSEcCtD
Flurandrenolide—Budesonide—NR3C1—prostate cancer	6.37e-05	0.0201	CrCbGaD
Flurandrenolide—Amcinonide—NR3C1—prostate cancer	6.37e-05	0.0201	CrCbGaD
Flurandrenolide—Medroxyprogesterone Acetate—SHBG—prostate cancer	6.37e-05	0.0201	CrCbGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—ZNF160—prostate cancer	6.23e-05	0.00492	CbGpPWpGaD
Flurandrenolide—Pruritus—Capecitabine—prostate cancer	6.2e-05	0.0028	CcSEcCtD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—SERPINE1—prostate cancer	6.17e-05	0.00487	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—EGR1—prostate cancer	6.13e-05	0.00484	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOA1—prostate cancer	6.09e-05	0.00481	CbGpPWpGaD
Flurandrenolide—Infection—Epirubicin—prostate cancer	6.07e-05	0.00274	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—PPARA—prostate cancer	6.03e-05	0.00477	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—NCOA1—prostate cancer	6.03e-05	0.00477	CbGpPWpGaD
Flurandrenolide—Rimexolone—NR3C1—prostate cancer	5.99e-05	0.0189	CrCbGaD
Flurandrenolide—NR3C1—Circadian Clock—HIF1A—prostate cancer	5.87e-05	0.00463	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—INS—prostate cancer	5.85e-05	0.00462	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AR—prostate cancer	5.84e-05	0.00462	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—ESR1—prostate cancer	5.81e-05	0.00459	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Prednisone—prostate cancer	5.75e-05	0.0026	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL10—prostate cancer	5.74e-05	0.00453	CbGpPWpGaD
Flurandrenolide—Rash—Docetaxel—prostate cancer	5.71e-05	0.00258	CcSEcCtD
Flurandrenolide—Dermatitis—Docetaxel—prostate cancer	5.7e-05	0.00258	CcSEcCtD
Flurandrenolide—Fluocinonide—NR3C1—prostate cancer	5.65e-05	0.0178	CrCbGaD
Flurandrenolide—Infection—Doxorubicin—prostate cancer	5.61e-05	0.00254	CcSEcCtD
Flurandrenolide—Medroxyprogesterone Acetate—AR—prostate cancer	5.59e-05	0.0176	CrCbGaD
Flurandrenolide—Rash—Capecitabine—prostate cancer	5.53e-05	0.0025	CcSEcCtD
Flurandrenolide—Pruritus—Prednisone—prostate cancer	5.53e-05	0.0025	CcSEcCtD
Flurandrenolide—Dermatitis—Capecitabine—prostate cancer	5.52e-05	0.0025	CcSEcCtD
Flurandrenolide—Alclometasone—NR3C1—prostate cancer	5.49e-05	0.0173	CrCbGaD
Flurandrenolide—Fluocinolone Acetonide—NR3C1—prostate cancer	5.49e-05	0.0173	CrCbGaD
Flurandrenolide—Flunisolide—NR3C1—prostate cancer	5.35e-05	0.0168	CrCbGaD
Flurandrenolide—Fludrocortisone—NR3C1—prostate cancer	5.35e-05	0.0168	CrCbGaD
Flurandrenolide—Paramethasone—NR3C1—prostate cancer	5.28e-05	0.0166	CrCbGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—prostate cancer	5.25e-05	0.00415	CbGpPWpGaD
Flurandrenolide—Ciclesonide—NR3C1—prostate cancer	5.2e-05	0.0164	CrCbGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—GSK3B—prostate cancer	5.11e-05	0.00404	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—prostate cancer	5.11e-05	0.00403	CbGpPWpGaD
Flurandrenolide—Methylprednisolone—NR3C1—prostate cancer	4.98e-05	0.0157	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—NCOA2—prostate cancer	4.95e-05	0.00391	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—CREBBP—prostate cancer	4.94e-05	0.0039	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—BAX—prostate cancer	4.93e-05	0.00389	CbGpPWpGaD
Flurandrenolide—Rash—Prednisone—prostate cancer	4.92e-05	0.00223	CcSEcCtD
Flurandrenolide—Dermatitis—Prednisone—prostate cancer	4.92e-05	0.00222	CcSEcCtD
Flurandrenolide—Dexamethasone—CYP17A1—prostate cancer	4.86e-05	0.0153	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—HIF1A—prostate cancer	4.84e-05	0.00382	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—GADD45A—prostate cancer	4.8e-05	0.00379	CbGpPWpGaD
Flurandrenolide—NR3C1—Circadian Clock—CREBBP—prostate cancer	4.79e-05	0.00379	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—PLAU—prostate cancer	4.79e-05	0.00378	CbGpPWpGaD
Flurandrenolide—Prednisolone—CYP2A6—prostate cancer	4.55e-05	0.0143	CrCbGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—PRKACB—prostate cancer	4.54e-05	0.00359	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—SHBG—prostate cancer	4.52e-05	0.0142	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—ESR1—prostate cancer	4.51e-05	0.00356	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Epirubicin—prostate cancer	4.5e-05	0.00203	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—SERPINE1—prostate cancer	4.49e-05	0.00355	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—prostate cancer	4.48e-05	0.00354	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—IL6—prostate cancer	4.45e-05	0.00351	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—APC—prostate cancer	4.36e-05	0.00345	CbGpPWpGaD
Flurandrenolide—Pruritus—Epirubicin—prostate cancer	4.32e-05	0.00195	CcSEcCtD
Flurandrenolide—NR3C1—Generic Transcription Pathway—TBX5—prostate cancer	4.32e-05	0.00341	CbGpPWpGaD
Flurandrenolide—Medroxyprogesterone Acetate—ESR1—prostate cancer	4.31e-05	0.0136	CrCbGaD
Flurandrenolide—Betamethasone—CYP19A1—prostate cancer	4.25e-05	0.0134	CrCbGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL1RN—prostate cancer	4.22e-05	0.00334	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—MDM2—prostate cancer	4.19e-05	0.00331	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—NCOA1—prostate cancer	4.17e-05	0.0033	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Doxorubicin—prostate cancer	4.16e-05	0.00188	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—prostate cancer	4.01e-05	0.00317	CbGpPWpGaD
Flurandrenolide—Pruritus—Doxorubicin—prostate cancer	4e-05	0.00181	CcSEcCtD
Flurandrenolide—Hydrocortamate—CYP3A4—prostate cancer	3.97e-05	0.0125	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—RXRA—prostate cancer	3.97e-05	0.00314	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—ESR2—prostate cancer	3.92e-05	0.00309	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—prostate cancer	3.91e-05	0.00309	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—TH—prostate cancer	3.89e-05	0.00307	CbGpPWpGaD
Flurandrenolide—Rash—Epirubicin—prostate cancer	3.85e-05	0.00174	CcSEcCtD
Flurandrenolide—Dermatitis—Epirubicin—prostate cancer	3.85e-05	0.00174	CcSEcCtD
Flurandrenolide—Medroxyprogesterone Acetate—NR3C1—prostate cancer	3.79e-05	0.0119	CrCbGaD
Flurandrenolide—Budesonide—CYP3A4—prostate cancer	3.69e-05	0.0116	CrCbGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—EGR1—prostate cancer	3.66e-05	0.00289	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—GSK3B—prostate cancer	3.6e-05	0.00285	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—CYP3A5—prostate cancer	3.6e-05	0.0113	CrCbGaD
Flurandrenolide—Rash—Doxorubicin—prostate cancer	3.56e-05	0.00161	CcSEcCtD
Flurandrenolide—Dermatitis—Doxorubicin—prostate cancer	3.56e-05	0.00161	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—prostate cancer	3.52e-05	0.00278	CbGpPWpGaD
Flurandrenolide—Prednisolone—NR3C1—prostate cancer	3.51e-05	0.0111	CrCbGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—GJA1—prostate cancer	3.49e-05	0.00275	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—prostate cancer	3.48e-05	0.00275	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—AR—prostate cancer	3.46e-05	0.00273	CbGpPWpGaD
Flurandrenolide—Betamethasone—NR3C1—prostate cancer	3.44e-05	0.0108	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—LPL—prostate cancer	3.43e-05	0.00271	CbGpPWpGaD
Flurandrenolide—Dexamethasone—CYP1B1—prostate cancer	3.37e-05	0.0106	CrCbGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—EP300—prostate cancer	3.36e-05	0.00266	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SERPINE1—prostate cancer	3.3e-05	0.0026	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—SRC—prostate cancer	3.27e-05	0.00258	CbGpPWpGaD
Flurandrenolide—NR3C1—Circadian Clock—EP300—prostate cancer	3.26e-05	0.00258	CbGpPWpGaD
Flurandrenolide—Drospirenone—PTGS2—prostate cancer	3.22e-05	0.0102	CrCbGaD
Flurandrenolide—Alclometasone—CYP3A4—prostate cancer	3.18e-05	0.01	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CXCL8—prostate cancer	3.14e-05	0.00248	CbGpPWpGaD
Flurandrenolide—Flunisolide—CYP3A4—prostate cancer	3.1e-05	0.00977	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CDKN1B—prostate cancer	3.06e-05	0.00242	CbGpPWpGaD
Flurandrenolide—Paramethasone—CYP3A4—prostate cancer	3.06e-05	0.00964	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—PPARA—prostate cancer	3.03e-05	0.0024	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL10—prostate cancer	3.02e-05	0.00239	CbGpPWpGaD
Flurandrenolide—Ciclesonide—CYP3A4—prostate cancer	3.01e-05	0.00949	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL2—prostate cancer	3e-05	0.00237	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—BAZ2A—prostate cancer	3e-05	0.00237	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—SSR2—prostate cancer	3e-05	0.00237	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ZNF160—prostate cancer	3e-05	0.00237	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—CTNNB1—prostate cancer	2.96e-05	0.00234	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—prostate cancer	2.96e-05	0.00234	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—HIF1A—prostate cancer	2.95e-05	0.00233	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CCND1—prostate cancer	2.92e-05	0.00231	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CTNNB1—prostate cancer	2.9e-05	0.00229	CbGpPWpGaD
Flurandrenolide—Methylprednisolone—CYP3A4—prostate cancer	2.89e-05	0.0091	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—LEP—prostate cancer	2.88e-05	0.00227	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—MMP9—prostate cancer	2.84e-05	0.00224	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—PTEN—prostate cancer	2.82e-05	0.00223	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—prostate cancer	2.76e-05	0.00218	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—HNRNPH1—prostate cancer	2.74e-05	0.00217	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—EP300—prostate cancer	2.69e-05	0.00213	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—NR3C1—prostate cancer	2.69e-05	0.00846	CrCbGaD
Flurandrenolide—Dexamethasone—CYP3A5—prostate cancer	2.68e-05	0.00845	CrCbGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IL2—prostate cancer	2.64e-05	0.00209	CbGpPWpGaD
Flurandrenolide—Dexamethasone—CYP2A6—prostate cancer	2.6e-05	0.00817	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—IRS1—prostate cancer	2.57e-05	0.00203	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NFIC—prostate cancer	2.55e-05	0.00201	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—HIF1A—prostate cancer	2.55e-05	0.00201	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—prostate cancer	2.52e-05	0.00199	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—prostate cancer	2.49e-05	0.00197	CbGpPWpGaD
Flurandrenolide—Dexamethasone—CYP19A1—prostate cancer	2.47e-05	0.00778	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—INS—prostate cancer	2.46e-05	0.00194	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RPN2—prostate cancer	2.4e-05	0.00189	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—prostate cancer	2.39e-05	0.00189	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—TGFB1—prostate cancer	2.39e-05	0.00189	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—IGF1—prostate cancer	2.38e-05	0.00188	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—EP300—prostate cancer	2.37e-05	0.00187	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—prostate cancer	2.36e-05	0.00186	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—MYC—prostate cancer	2.34e-05	0.00185	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—TGFB1—prostate cancer	2.34e-05	0.00185	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NPPA—prostate cancer	2.3e-05	0.00182	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—QARS—prostate cancer	2.27e-05	0.00179	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—MED12—prostate cancer	2.27e-05	0.00179	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—SERPINE1—prostate cancer	2.26e-05	0.00178	CbGpPWpGaD
Flurandrenolide—Medroxyprogesterone Acetate—CYP3A4—prostate cancer	2.2e-05	0.00692	CrCbGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—prostate cancer	2.09e-05	0.00165	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CREBBP—prostate cancer	2.08e-05	0.00164	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—TBX5—prostate cancer	2.08e-05	0.00164	CbGpPWpGaD
Flurandrenolide—Prednisolone—CYP3A4—prostate cancer	2.04e-05	0.00641	CrCbGaD
Flurandrenolide—Dexamethasone—NR3C1—prostate cancer	2e-05	0.00631	CrCbGaD
Flurandrenolide—Betamethasone—CYP3A4—prostate cancer	2e-05	0.00628	CrCbGaD
Flurandrenolide—Betamethasone—PTGS2—prostate cancer	1.95e-05	0.00615	CrCbGaD
Flurandrenolide—NR3C1—Gene Expression—EIF3H—prostate cancer	1.93e-05	0.00153	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—TP53—prostate cancer	1.93e-05	0.00152	CbGpPWpGaD
Flurandrenolide—Dexamethasone—CYP2E1—prostate cancer	1.84e-05	0.0058	CrCbGaD
Flurandrenolide—Dexamethasone—CYP2C19—prostate cancer	1.82e-05	0.00575	CrCbGaD
Flurandrenolide—Dexamethasone—CYP1A1—prostate cancer	1.82e-05	0.00573	CrCbGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NCOA2—prostate cancer	1.81e-05	0.00143	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—CTNNB1—prostate cancer	1.76e-05	0.00139	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL6—prostate cancer	1.76e-05	0.00139	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—PARP1—prostate cancer	1.75e-05	0.00138	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—CDKN1A—prostate cancer	1.72e-05	0.00136	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—TP53—prostate cancer	1.7e-05	0.00134	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—ESR2—prostate cancer	1.65e-05	0.00131	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CXCL8—prostate cancer	1.65e-05	0.00131	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CASP3—prostate cancer	1.58e-05	0.00125	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—TET2—prostate cancer	1.57e-05	0.00124	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—MBD2—prostate cancer	1.57e-05	0.00124	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—CYP3A4—prostate cancer	1.56e-05	0.00491	CrCbGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IL6—prostate cancer	1.55e-05	0.00123	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RPL12—prostate cancer	1.54e-05	0.00122	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—STAT3—prostate cancer	1.54e-05	0.00121	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	1.52e-05	0.0012	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NCOA1—prostate cancer	1.52e-05	0.0012	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—AR—prostate cancer	1.46e-05	0.00115	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—RXRA—prostate cancer	1.45e-05	0.00115	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—prostate cancer	1.45e-05	0.00114	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—prostate cancer	1.43e-05	0.00113	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—TGFB1—prostate cancer	1.43e-05	0.00113	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—EIF3A—prostate cancer	1.42e-05	0.00112	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—EP300—prostate cancer	1.42e-05	0.00112	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—VEGFA—prostate cancer	1.34e-05	0.00106	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—VDR—prostate cancer	1.31e-05	0.00104	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—DNMT3B—prostate cancer	1.19e-05	0.000943	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RPL10—prostate cancer	1.17e-05	0.000925	CbGpPWpGaD
Flurandrenolide—Dexamethasone—CYP3A4—prostate cancer	1.16e-05	0.00366	CrCbGaD
Flurandrenolide—NR3C1—Gene Expression—HIST1H2BG—prostate cancer	1.15e-05	0.000908	CbGpPWpGaD
Flurandrenolide—Dexamethasone—PTGS2—prostate cancer	1.14e-05	0.00358	CrCbGaD
Flurandrenolide—NR3C1—Gene Expression—NPPA—prostate cancer	1.11e-05	0.000877	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—HIST1H4H—prostate cancer	1.11e-05	0.000877	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—PPARA—prostate cancer	1.11e-05	0.000875	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—MED12—prostate cancer	1.09e-05	0.000862	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—IL6—prostate cancer	1.07e-05	0.000849	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—ESR1—prostate cancer	1e-05	0.000792	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL6—prostate cancer	9.28e-06	0.000733	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RPS19—prostate cancer	9.28e-06	0.000733	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—DNMT1—prostate cancer	8.87e-06	0.000701	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—CREBBP—prostate cancer	8.79e-06	0.000695	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NCOA2—prostate cancer	8.71e-06	0.000688	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—EZH2—prostate cancer	8.59e-06	0.000679	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—PARP1—prostate cancer	8.41e-06	0.000664	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—SERPINE1—prostate cancer	8.25e-06	0.000651	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—HSPA1A—prostate cancer	7.96e-06	0.000629	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ESR2—prostate cancer	7.96e-06	0.000629	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NCOA1—prostate cancer	7.34e-06	0.00058	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—AR—prostate cancer	7.03e-06	0.000556	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RXRA—prostate cancer	6.98e-06	0.000551	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—SIRT1—prostate cancer	6.41e-06	0.000507	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—VDR—prostate cancer	6.32e-06	0.000499	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ERCC2—prostate cancer	5.78e-06	0.000457	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—PPARA—prostate cancer	5.33e-06	0.000421	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—MYC—prostate cancer	5.22e-06	0.000412	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ESR1—prostate cancer	4.83e-06	0.000382	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—CREBBP—prostate cancer	4.23e-06	0.000334	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—SERPINE1—prostate cancer	3.97e-06	0.000314	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—MYC—prostate cancer	2.51e-06	0.000198	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—AKT1—prostate cancer	1.74e-06	0.000138	CbGpPWpGaD
